1. Home
  2. KULR vs BDTX Comparison

KULR vs BDTX Comparison

Compare KULR & BDTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo KULR Technology Group Inc.

KULR

KULR Technology Group Inc.

HOLD

Current Price

$3.93

Market Cap

176.2M

Sector

Technology

ML Signal

HOLD

Logo Black Diamond Therapeutics Inc.

BDTX

Black Diamond Therapeutics Inc.

HOLD

Current Price

$1.97

Market Cap

171.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
KULR
BDTX
Founded
2013
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Electrical Products
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
176.2M
171.9M
IPO Year
2016
2020

Fundamental Metrics

Financial Performance
Metric
KULR
BDTX
Price
$3.93
$1.97
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$9.67
AVG Volume (30 Days)
2.0M
2.3M
Earning Date
05-15-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
130.71
EPS
N/A
N/A
Revenue
$1,274,028.00
N/A
Revenue This Year
$123.93
N/A
Revenue Next Year
$63.38
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.94
$1.60
52 Week High
$7.49
$4.94

Technical Indicators

Market Signals
Indicator
KULR
BDTX
Relative Strength Index (RSI) 52.46 48.94
Support Level $3.48 $1.60
Resistance Level $4.40 $2.30
Average True Range (ATR) 0.37 0.14
MACD -0.01 0.06
Stochastic Oscillator 61.69 73.40

Price Performance

Historical Comparison
KULR
BDTX

About KULR KULR Technology Group Inc.

KULR Technology Group Inc develops and commercializes high-performance thermal management technologies for electronics, batteries, and other components. The company is focused on targeting the following applications: electric vehicles and autonomous driving systems, artificial intelligence and Cloud computing, energy storage, 5G communication technologies, and other consumer and industrial devices. The Company operated two segments -EMP and Mining of Digital Assets.

About BDTX Black Diamond Therapeutics Inc.

Black Diamond Therapeutics Inc is a clinical-stage oncology company developing MasterKey therapies that target families of oncogenic mutations in patients with cancer. The foundation of companies has been built upon a deep understanding of cancer genetics, onco-protein structure and function, and medicinal chemistry. Its clinical-stage program, silevertinib (formerly BDTX-1535), a brain-penetrant, fourth-generation epidermal growth factor receptor (EGFR) MasterKey inhibitor, is currently being studied in a Phase 2 clinical trial in patients with epidermal growth factor receptor mutant (EGFRm) non-small cell lung cancer (NSCLC). The Company manages its operations as a single operating segment and single reportable segment.

Share on Social Networks: